GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Atara Biotherapeutics Inc (STU:AT2) » Definitions » Price-to-Owner-Earnings

Atara Biotherapeutics (STU:AT2) Price-to-Owner-Earnings : (As of May. 26, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Atara Biotherapeutics Price-to-Owner-Earnings?

As of today (2024-05-26), Atara Biotherapeutics's share price is €0.5702. Atara Biotherapeutics does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Atara Biotherapeutics's Price-to-Owner-Earnings or its related term are showing as below:


STU:AT2's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 33.37
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-05-26), Atara Biotherapeutics's share price is €0.5702. Atara Biotherapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was €-1.97. Therefore, Atara Biotherapeutics's PE Ratio for today is At Loss.

As of today (2024-05-26), Atara Biotherapeutics's share price is €0.5702. Atara Biotherapeutics's EPS without NRI for the trailing twelve months (TTM) ended in was €-1.97. Therefore, Atara Biotherapeutics's PE Ratio without NRI for today is At Loss.


Atara Biotherapeutics Price-to-Owner-Earnings Historical Data

The historical data trend for Atara Biotherapeutics's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Atara Biotherapeutics Price-to-Owner-Earnings Chart

Atara Biotherapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Atara Biotherapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Atara Biotherapeutics's Price-to-Owner-Earnings

For the Biotechnology subindustry, Atara Biotherapeutics's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Atara Biotherapeutics's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Atara Biotherapeutics's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Atara Biotherapeutics's Price-to-Owner-Earnings falls into.



Atara Biotherapeutics Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Atara Biotherapeutics's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=0.5702/-1.62
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Atara Biotherapeutics  (STU:AT2) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Atara Biotherapeutics Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Atara Biotherapeutics's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Atara Biotherapeutics (STU:AT2) Business Description

Traded in Other Exchanges
Address
2380 Conejo Spectrum St, Suite 200, Thousand Oaks, CA, USA, 91320
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).

Atara Biotherapeutics (STU:AT2) Headlines

No Headlines